Clinical role of a new prognostic score using platelet-tolymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy

Tetsuzo Tagawa, Masaki Anraku, Yosuke Morodomi, Tomoyoshi Takenaka, Tatsuro Okamoto, Mitsuhiro Takenoyama, Yukito Ichinose, Yoshihiko Maehara, B. C. John Cho, Ronald Feld, Ming Sound Tsao, Natasha Leighl, Andrea Bezjak, Shaf Keshavjee, Marc de Perrot

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: To investigate the prognostic value of platelet-to-lymphocyte ratio (PLR) and create a new prognostic score in patients with malignant pleural mesothelioma (MPM) undergoing extrapleural pneumonectomy (EPP). Methods: Of 85 patients who underwent EPP for MPM over 10 years at Toronto General Hospital, 65 patients whose blood test results before initial therapy were available were retrospectively analyzed as a training cohort to identify and develop a prognostic score. Receiver operating characteristic (ROC) analysis was performed to examine cutoff values of hematologic parameters for survival. The prognostic score was externally validated in a cohort of 32 patients who underwent EPP for MPM over 13 years at two institutes in Japan. Results: In the training cohort, multivariate analysis confirmed sex (P=0.0053) and PLR (P=0.049) as independent predictors of overall survival. The prognostic score was established using sex and PLR. The score was defined as follows: female:male =0:1 point; PLR < 215: > 215=0:1 point. The patients were classified into three risk groups according to the sum of the points: risk 0 (0 point), 1 (1 point), and 2 (2 points). Median survival time of the patients in the training cohort according to the risk groups were not reached, 32.0 and 19.4 months for risk 0 (n=6), 1 (n=36) and 2 (n=23), respectively (P=0.0006). In the validation cohort, median survival time was not reached, 45.9 and 14.5 months for risk 0 (n=4), 1 (n=18) and 2 (n=10), respectively (P=0.0002). Conclusions: The new prognostic score using PLR is simple and useful for predicting the prognosis of patients with MPM undergoing EPP. Further study should be done to examine the role of this scoring system to optimize treatment strategy.

Original languageEnglish
Pages (from-to)1898-1906
Number of pages9
JournalJournal of Thoracic Disease
Volume7
Issue number11
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Pneumonectomy
Blood Platelets
Lymphocytes
Survival
Hematologic Tests
Malignant Mesothelioma
ROC Curve
General Hospitals
Japan
Cohort Studies
Multivariate Analysis
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Cite this

Clinical role of a new prognostic score using platelet-tolymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy. / Tagawa, Tetsuzo; Anraku, Masaki; Morodomi, Yosuke; Takenaka, Tomoyoshi; Okamoto, Tatsuro; Takenoyama, Mitsuhiro; Ichinose, Yukito; Maehara, Yoshihiko; John Cho, B. C.; Feld, Ronald; Tsao, Ming Sound; Leighl, Natasha; Bezjak, Andrea; Keshavjee, Shaf; de Perrot, Marc.

In: Journal of Thoracic Disease, Vol. 7, No. 11, 01.01.2015, p. 1898-1906.

Research output: Contribution to journalArticle

Tagawa, T, Anraku, M, Morodomi, Y, Takenaka, T, Okamoto, T, Takenoyama, M, Ichinose, Y, Maehara, Y, John Cho, BC, Feld, R, Tsao, MS, Leighl, N, Bezjak, A, Keshavjee, S & de Perrot, M 2015, 'Clinical role of a new prognostic score using platelet-tolymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy', Journal of Thoracic Disease, vol. 7, no. 11, pp. 1898-1906. https://doi.org/10.3978/j.issn.2072-1439.2015.11.15
Tagawa, Tetsuzo ; Anraku, Masaki ; Morodomi, Yosuke ; Takenaka, Tomoyoshi ; Okamoto, Tatsuro ; Takenoyama, Mitsuhiro ; Ichinose, Yukito ; Maehara, Yoshihiko ; John Cho, B. C. ; Feld, Ronald ; Tsao, Ming Sound ; Leighl, Natasha ; Bezjak, Andrea ; Keshavjee, Shaf ; de Perrot, Marc. / Clinical role of a new prognostic score using platelet-tolymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy. In: Journal of Thoracic Disease. 2015 ; Vol. 7, No. 11. pp. 1898-1906.
@article{32d31f2bbf014c408f635a6e0a0e1297,
title = "Clinical role of a new prognostic score using platelet-tolymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy",
abstract = "Background: To investigate the prognostic value of platelet-to-lymphocyte ratio (PLR) and create a new prognostic score in patients with malignant pleural mesothelioma (MPM) undergoing extrapleural pneumonectomy (EPP). Methods: Of 85 patients who underwent EPP for MPM over 10 years at Toronto General Hospital, 65 patients whose blood test results before initial therapy were available were retrospectively analyzed as a training cohort to identify and develop a prognostic score. Receiver operating characteristic (ROC) analysis was performed to examine cutoff values of hematologic parameters for survival. The prognostic score was externally validated in a cohort of 32 patients who underwent EPP for MPM over 13 years at two institutes in Japan. Results: In the training cohort, multivariate analysis confirmed sex (P=0.0053) and PLR (P=0.049) as independent predictors of overall survival. The prognostic score was established using sex and PLR. The score was defined as follows: female:male =0:1 point; PLR < 215: > 215=0:1 point. The patients were classified into three risk groups according to the sum of the points: risk 0 (0 point), 1 (1 point), and 2 (2 points). Median survival time of the patients in the training cohort according to the risk groups were not reached, 32.0 and 19.4 months for risk 0 (n=6), 1 (n=36) and 2 (n=23), respectively (P=0.0006). In the validation cohort, median survival time was not reached, 45.9 and 14.5 months for risk 0 (n=4), 1 (n=18) and 2 (n=10), respectively (P=0.0002). Conclusions: The new prognostic score using PLR is simple and useful for predicting the prognosis of patients with MPM undergoing EPP. Further study should be done to examine the role of this scoring system to optimize treatment strategy.",
author = "Tetsuzo Tagawa and Masaki Anraku and Yosuke Morodomi and Tomoyoshi Takenaka and Tatsuro Okamoto and Mitsuhiro Takenoyama and Yukito Ichinose and Yoshihiko Maehara and {John Cho}, {B. C.} and Ronald Feld and Tsao, {Ming Sound} and Natasha Leighl and Andrea Bezjak and Shaf Keshavjee and {de Perrot}, Marc",
year = "2015",
month = "1",
day = "1",
doi = "10.3978/j.issn.2072-1439.2015.11.15",
language = "English",
volume = "7",
pages = "1898--1906",
journal = "Journal of Thoracic Disease",
issn = "2072-1439",
publisher = "Pioneer Bioscience Publishing Company (PBPC)",
number = "11",

}

TY - JOUR

T1 - Clinical role of a new prognostic score using platelet-tolymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy

AU - Tagawa, Tetsuzo

AU - Anraku, Masaki

AU - Morodomi, Yosuke

AU - Takenaka, Tomoyoshi

AU - Okamoto, Tatsuro

AU - Takenoyama, Mitsuhiro

AU - Ichinose, Yukito

AU - Maehara, Yoshihiko

AU - John Cho, B. C.

AU - Feld, Ronald

AU - Tsao, Ming Sound

AU - Leighl, Natasha

AU - Bezjak, Andrea

AU - Keshavjee, Shaf

AU - de Perrot, Marc

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background: To investigate the prognostic value of platelet-to-lymphocyte ratio (PLR) and create a new prognostic score in patients with malignant pleural mesothelioma (MPM) undergoing extrapleural pneumonectomy (EPP). Methods: Of 85 patients who underwent EPP for MPM over 10 years at Toronto General Hospital, 65 patients whose blood test results before initial therapy were available were retrospectively analyzed as a training cohort to identify and develop a prognostic score. Receiver operating characteristic (ROC) analysis was performed to examine cutoff values of hematologic parameters for survival. The prognostic score was externally validated in a cohort of 32 patients who underwent EPP for MPM over 13 years at two institutes in Japan. Results: In the training cohort, multivariate analysis confirmed sex (P=0.0053) and PLR (P=0.049) as independent predictors of overall survival. The prognostic score was established using sex and PLR. The score was defined as follows: female:male =0:1 point; PLR < 215: > 215=0:1 point. The patients were classified into three risk groups according to the sum of the points: risk 0 (0 point), 1 (1 point), and 2 (2 points). Median survival time of the patients in the training cohort according to the risk groups were not reached, 32.0 and 19.4 months for risk 0 (n=6), 1 (n=36) and 2 (n=23), respectively (P=0.0006). In the validation cohort, median survival time was not reached, 45.9 and 14.5 months for risk 0 (n=4), 1 (n=18) and 2 (n=10), respectively (P=0.0002). Conclusions: The new prognostic score using PLR is simple and useful for predicting the prognosis of patients with MPM undergoing EPP. Further study should be done to examine the role of this scoring system to optimize treatment strategy.

AB - Background: To investigate the prognostic value of platelet-to-lymphocyte ratio (PLR) and create a new prognostic score in patients with malignant pleural mesothelioma (MPM) undergoing extrapleural pneumonectomy (EPP). Methods: Of 85 patients who underwent EPP for MPM over 10 years at Toronto General Hospital, 65 patients whose blood test results before initial therapy were available were retrospectively analyzed as a training cohort to identify and develop a prognostic score. Receiver operating characteristic (ROC) analysis was performed to examine cutoff values of hematologic parameters for survival. The prognostic score was externally validated in a cohort of 32 patients who underwent EPP for MPM over 13 years at two institutes in Japan. Results: In the training cohort, multivariate analysis confirmed sex (P=0.0053) and PLR (P=0.049) as independent predictors of overall survival. The prognostic score was established using sex and PLR. The score was defined as follows: female:male =0:1 point; PLR < 215: > 215=0:1 point. The patients were classified into three risk groups according to the sum of the points: risk 0 (0 point), 1 (1 point), and 2 (2 points). Median survival time of the patients in the training cohort according to the risk groups were not reached, 32.0 and 19.4 months for risk 0 (n=6), 1 (n=36) and 2 (n=23), respectively (P=0.0006). In the validation cohort, median survival time was not reached, 45.9 and 14.5 months for risk 0 (n=4), 1 (n=18) and 2 (n=10), respectively (P=0.0002). Conclusions: The new prognostic score using PLR is simple and useful for predicting the prognosis of patients with MPM undergoing EPP. Further study should be done to examine the role of this scoring system to optimize treatment strategy.

UR - http://www.scopus.com/inward/record.url?scp=84949959532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949959532&partnerID=8YFLogxK

U2 - 10.3978/j.issn.2072-1439.2015.11.15

DO - 10.3978/j.issn.2072-1439.2015.11.15

M3 - Article

AN - SCOPUS:84949959532

VL - 7

SP - 1898

EP - 1906

JO - Journal of Thoracic Disease

JF - Journal of Thoracic Disease

SN - 2072-1439

IS - 11

ER -